Respiratory therapies company Cornerstone Therapeutics has named a Quintiles executive to become the company’s new chief financial officer.
Vincent Morgus has been senior vice president, corporate development at Quintiles since 2003. His new job at Cary, North Carolina-based Cornerstone (NASDAQ:CRTX) started on Feb. 1.
Morgus is a veteran of Quintiles. He started at the clinical research organization in 1994 and progressed through a variety of financial management positions in the company. Before working at Quintiles, Morgus worked at Q+E Software and DaVinci Systems Corp. He started his career as an auditor for Arthur Andersen.
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Morgus replaces former CFO David Price, who left the company last June.
Cornerstone specializes in respiratory drugs. Its top-selling product is Curosurf, a treatment for respiratory distress syndrome in infants that generated $23.7 million in sales through the nine months ending Sept. 30, 2010.